UncategorizedFDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool Sumain Faisal1 week ago01 mins FDA approves Novartis’ Pluvicto for advanced prostate cancer patients who have received ARPI therapy. read moreJoin the newsletterSubscribe to get our latest content by email.SubscribeWe respect your privacy. Unsubscribe at any time.Built with Kit Post navigation Previous: JP Morgan’s Stock Picks In The Power Sector Amid Regulatory UncertaintyNext: European Drug Regulator Gives Thumbs Down To Eli Lilly’s Alzheimer’s Drug, Analyst Says It Is Incremental Win For Biogen Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.
Blaze Star 3,000 Light-Years Away Set To Explode in Rare Event Visible From Earth: ‘Once-In-A-Lifetime Event’ Sumain Faisal2 hours ago 0
Global Hedge Funds and ETFs Offload Over $40 Billion in Stocks Following Trump’s Tariff Announcement Sumain Faisal3 hours ago 0
Conservative Nonprofit Launches Court Challenge to Trump Tariffs — A Sign of Things To Come? Sumain Faisal3 hours ago 0
Peter Lynch’s Advice: ‘If You Can’t Explain to an 11-Year-Old in Two Minutes or Less Why You Own the Stock, You Shouldn’t Own It’ Sumain Faisal3 hours ago 0